Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Cybin Inc. N.CYBN

Alternate Symbol(s):  CYBN

Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders, all protected under its ever-growing IP portfolio.


Recent & Breaking News (NEO:CYBN)

Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds

Business Wire 7 days ago

Mindset Pharma Provides Strategic Intellectual Property License to Cybin

GlobeNewswire 7 days ago

Cybin to Participate in Upcoming Scientific and Investor Conferences

Business Wire 13 days ago

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

Business Wire September 20, 2022

Cybin Announces Final Adelia Milestone Achievement

Business Wire August 31, 2022

Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

Business Wire August 30, 2022

Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Business Wire August 25, 2022

Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial

Business Wire August 17, 2022

Cybin Announces Results of Shareholders' Meeting

Business Wire August 15, 2022

Cybin Announces Up to USD$35 Million At-The-Market Equity Program

Business Wire August 8, 2022

Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights

Business Wire August 8, 2022

Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference

Business Wire July 28, 2022

Cybin Announces Date of Annual Meeting of Shareholders

Business Wire July 25, 2022

Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Business Wire July 12, 2022

Cybin Inc. (NEO:CYBN) completes acquisition of Phase 1 DMT Study from Entheon Biomedical

Dave Jackson July 11, 2022

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

Business Wire July 11, 2022

Cybin Announces Additional Adelia Milestone Achievement

Business Wire June 27, 2022

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

Business Wire June 27, 2022

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

Business Wire June 22, 2022

Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

Business Wire June 16, 2022